Response rate for alemtuzumab in refractory, relapsed, and treatment-naive SAA
| Response . | Refractory study (n = 54) . | P . | Relapse study (n = 25) . | Treatment-naive study (n = 16) . | |
|---|---|---|---|---|---|
| Rabbit ATG (95% CI) . | Alemtuzumab (95% CI) . | Alemtuzumab (95% CI) . | Alemtuzumab (95% CI) . | ||
| 3-mo | 19% (3-34) | 19% (3-34) | 1.00 | 48% (27-69) | 19% (0-40) |
| 6-mo | 33% (14-52) | 37% (18-57) | .78 | 56% (35-77) | 19% (0-40) |
| Response . | Refractory study (n = 54) . | P . | Relapse study (n = 25) . | Treatment-naive study (n = 16) . | |
|---|---|---|---|---|---|
| Rabbit ATG (95% CI) . | Alemtuzumab (95% CI) . | Alemtuzumab (95% CI) . | Alemtuzumab (95% CI) . | ||
| 3-mo | 19% (3-34) | 19% (3-34) | 1.00 | 48% (27-69) | 19% (0-40) |
| 6-mo | 33% (14-52) | 37% (18-57) | .78 | 56% (35-77) | 19% (0-40) |
In the refractory study, patients initially unresponsive to horse ATG + cyclosporine were randomized to rabbit ATG + cyclosporine (n = 27) and alemtuzumab (n = 27). In patients with relapsed disease, alemtuzumab was administered in a single-arm (nonrandomized) study. P is for the comparison between rabbit ATG and alemtuzumab in the refractory study.